Yibai Pharmaceutical Co., Ltd. Zhou Yi: Yibai is a respected pharmaceutical company in China

[China Pharmaceutical network enterprise news] a few days ago, the 2018 Guizhou "top 100" enterprise press conference themed "practice high quality, strive for national enterprise" was held in Guiyang, and the list of Guizhou "top 100" enterprises was released Guizhou Maotai Group ranked first among the "top 100" enterprises, and Guizhou Laoganma and Yibai pharmaceutical are in the top 10 private enterprises At the meeting, China net invited director Zhou Yi of Yibai pharmaceutical to make an interview and report Chinanet: Yibai pharmaceutical, as the representative of Guizhou top 100 enterprises, in the face of the development of pharmaceutical industry closely related to people's life and health, first of all, it is necessary to ensure the safety and quality of products, second, it is necessary to do a good job in product brand development What are the new measures of Yibai pharmaceutical in promoting the development of traditional Chinese medicine? Zhou Yi: with the mission of "medical product provider and health service provider", Yibai pharmaceutical takes the promotion of traditional Chinese medicine and national medicine as its own responsibility In addition to the investment in research and development, it has also made great efforts in the in-depth exploration of traditional Chinese medicine and the development of national medicine, including our commitment to the improvement of the quality and quality of the whole product We have spent a lot of energy, effort and effort to achieve today's results Many of our products are among the best in the market segment, and we were nominated for the quality award of governor of Guizhou Province in 2017 However, compared with the international and domestic enterprises, we still have a big gap In the development of traditional Chinese medicine, it is far from in place and still has a long way to go We will continue to make efforts in new product research and development, herbal medicine planting, herbal medicine extraction, production process, product quality, clinical research, market promotion, etc Chinanet: in recent years, under the influence of bidding price reduction, medical insurance fee control and other policies, the growth rate of Yibai pharmaceutical's extension is beginning to show signs of weakness In such a situation, what measures will your company take next to achieve growth? Zhou Yi: this question is very acute We should say that we have a deep understanding of the deep-seated problems in the pharmaceutical industry It's true that as you said, the development difficulties of traditional Chinese medicine injection, including the national bidding price limit, the hospital's limit and so on, should encounter some difficulties for pharmaceutical enterprises, especially for Chinese patent medicine enterprises in the past two years But in the face of difficulties, we think it's objective and temporary Don't complain, find more reasons from yourself, explore more potential, and build your future core competitiveness For example, in terms of product diversification, we have made corresponding preparations in the early years This is not only seen in the past two years It can be said that it has been laid out ten years ago We have successively acquired some companies and enriched the product composition of the company Such diversified product reserves can maintain the healthy and sustainable development of the enterprise At the same time, we continue to increase the marketing of our products More than 80% of Yibai's product sales come from the first and second tier cities In the county market, we still have a lot of space Especially with the deepening of national medical reform and the gradual implementation of hierarchical diagnosis and treatment, a very large market will be formed at the grassroots level We have a lot of very good products, which are also very suitable for the grass-roots medical market I believe that after a period of efforts, we can make up for the fatigue or decline caused by this objective factor Chinanet: can you tell us about the brand strategy, influence and new product development of Yibai pharmaceutical? Zhou Yi: I think there are new elements in Yibai's brand strategy and influence, which are mainly reflected in the company's medical service sector Yibai's medical services have been low-key for many years In 2017, its growth rate has exceeded that of the pharmaceutical sector, and medical service is a very important sector of Yibai's big health strategy Research and development is the foundation of Yibai, and Yibai has always attached great importance to product research and development At present, a seedling medicine engineering research center is located in our Yibai Industrial Park, and has just passed the national site acceptance, which also shows that Yibai has a high level of technology in management and research and development The R & D of every Yibai product is to keep improving We know our social responsibility and sense of mission very well At present, the company's management, talent and technology introduction are all measured by international standards to ensure that the development of Yibai pharmaceutical will have a higher level in the future Chinanet: Thank you, director Zhou Thank you very much for your interview with Chinanet.